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Abstract: Infectious bronchitis (IB) is a notable disease of poultry flocks that results in economic loss. As a consequence of the presence
of various IB virus (IBV) serotypes, control strategies, such as vaccination, should be replaced by provide broad protective immunity
against the disease to date. Gram-positive enhancer matrix particles, or so-called bacterium like particles (BLPs), obtained from
the bacterium Lactococcus lactis (L. lactis), have demonstrated an adjuvancy effect by providing demanding mucosal and humoral
immune responses, as well as a protective cellular immunity whenever delivered admixed with a vaccine via intranasal or intraocular
administration. In this study, for the first time, attempts were made to investigate the impact of an IBV vaccine supplemented by various
doses of BLPs on induced levels of humoral immunity against IB. For this purpose, increasing doses of derived BLPs (0, 0.15, 0.3, and 0.6
mg dry weight per bird) were admixed with IBV live attenuated H120 serotype vaccine, and were delivered via ocular administration to
4 equal groups of 10 specific pathogen-free (SPF) chickens in 4 groups: control, BLP1, BLP2, and BLP3, respectively. In addition, 10 SPF
chickens that were not immunized comprised the Unvaccinated group. Blood was collected from 5 members of each group weekly for 35
days. Levels of IgG antibodies in the sera were then assayed using ELISA. Weight gain and the feed conversion ratio of each group were
also recorded weekly. Finally, 3 birds from each group were necropsied to evaluate probable lesions. The best results were obtained in the
BLP1 group, with IBV vaccination at a low dose of admixed BLPs boosted immediate anti-IBV humoral responses; however, the results
were not significantly different from those of the Control group, but were still feasible enough for application in the field. In conclusion,
BLPs could be a desirable adjuvant for IBV vaccines to increase immunity in chickens.
Key words: Bacterium like particles, IgG, adjuvant, infectious bronchitis, chicken

1. Introduction
Infectious bronchitis (IB) is a highly prevalent respiratory
disease in chickens. The IB virus (IBV) enters through
mucosal surfaces of the respiratory system, where
virus replication also occurs. Subsequent to a viremia,
the virus infects the kidneys, and gastrointestinal and
urogenital tracts. Infection of the mentioned organs
causes symptoms such as conjunctivitis, respiratory
distress, and pathological alterations in the kidneys and
trachea, as well as poor weight gain and a low number
of eggs in broilers and layers, respectively [1]. In the case
of existing accompanied secondary bacterial infection,
high mortality is expected from the disease. Thus, IB has
a significant economic influence on the poultry industry
[2]. The causing agent is a gamma-coronavirus possessing
4 structural proteins, and among them, the S protein (S1

and S2 subunits) is responsible for attachment and entry
through the cells [1]. These subunits are exploited in virus
identification and antigenic neutralization, and along with
a nucleocapsid protein, which contains CTL-inducing
epitopes, are capable of triggering host immune responses.
Differences in the amino acid sequence of the S1 subunit
gene, in addition to recombination between IBV strains,
result in the emergence of multiple new variants that are
not cross-protected. Apparently, the use of live attenuated
vaccine types or the presence of multiple concurrent
infections of different IBV serotypes also contributes to
this recombination process. Thus, some countries only
allow vaccination using one or a few vaccine types, which
makes strategies for preventing IB even more complicated.
As a consequence, controlling IB has not been completely
achieved thus far [3–6].

* Correspondence: ghaniei@um.ac.ir

534

This work is licensed under a Creative Commons Attribution 4.0 International License.

TOHIDI et al. / Turk J Vet Anim Sci
It has been revealed that while no association exists
between circulating antibodies and IB protection [6], both
the local antibody response and cell-mediated immunity
correlate greatly with protection. Nevertheless, monitoring
IgG antibodies still remains as an important method for
evaluating the immune response to an IBV challenge [7].
IB could initially be prevented by considering
vaccination and biosecurity methods. Immunization by
either live or inactivated vaccines of various serotypes has
been recognized as the main control strategy against IB. Due
to the requirements of multiple immunizations, such as large
doses of adjuvants as well as live priming, the application of
inactivated vaccines is costly and even less efficient when
compared to live types. The existence of so many IBV
strains, along with their antigenic alterations, is a huge
burden for highly protective immunization. To develop an
efficient anti-IBV vaccine, factors such as age, maternallyderived antibodies (MDAs), and the immune competence
of the bird, along with immunogenicity of the vaccine, the
virulence, and type of the challenge strain, as well as the
interval between vaccination and the challenge, should be
considered. Correspondingly, various novel promising IB
vaccines have been developed; however, their application in
the field has been challenged by existing drawbacks, such as
the low efficiency and immunogenicity of DNA and peptide
vaccines, respectively, as well as safety concerns about the
cytotoxicity of the components of nanoparticle vaccine
delivery, along with difficulty in maintaining stability and
displaying antigens on nanoparticles [1,3,8–10].
Wang [11] has cited that Roozmalen et al. developed
an antigen delivery platform.. in his paper.so the number
should be placed at the end of statement. developed an
antigen delivery platform comprising bacterium-like
particles (BLPs) for mucosal vaccines. The BLPs were
derived from Lactococcus lactis (L. lactis), a nonpathogenic
gram-positive bacterium that is considered as a generally
recognized and safe organism. As BLPs are the size of a
bacterium, their uptake by membranous cells is easily
facilitated [12]. Their advantages comprise reducing
secondary effects, the applicability of either a monovalent
or a polyvalent vaccine, along with decreasing bacterial
colonization and amplification in the lungs, being easily
administered for mass immunization, not requiring booster
immunization, triggering both the systemic and mucosal
immune systems, possessing a higher binding capacity,
as well as less anticarrier response, when compared to to
a living lactic acid bacteria (LAB) [13]. Surprisingly, their
capacity for being stored without the need for a cold chain
over a long period of time was also noticeable [14]. BLPs
are able to reduce the bacterial load in the lungs [14].
Additionally, it was found that when a secondary bacterial
infection also existed, the mortality of young chickens
caused by IBV was higher [15]. Thus, BLPs could probably

be a great advantage against mortality from IB, particularly
in young chickens.
In the current experiment, the influence of BLPs admixed
with an IBV vaccine delivered via ocular administration
on levels of anti-IBV serum IgGs of specific pathogen-free
(SPF) chickens was investigated and attempts were made
to discover the proper dose of BLPs that induced the best
humoral immune response against IB. Performance data
and necropsy lesions of the birds were also evaluated. To
our knowledge, it was the first application of BLPs in favor
of poultry health.
2. Materials and methods
2.1. BLP preparation
Lyophilized L. lactis was obtained from a microorganism
bank. Afterwards, it was transferred into a proper culture
medium (M17 broth supplemented with glucose). The
inoculated bacterium in liquid culture medium was then
centrifuged at 18,000 rpm for 10 min before washing
to remove the surface solution and subsequently, 10%
trichloroacetic acid was added to the pellet. Following
vortexing, the suspension was placed in boiling water for
5 min. The resultant solution was centrifuged and then the
pellet was washed with phosphate-buffered saline (PBS).
After the last centrifugation, PBS was added to the pellet.
Finally, it was stored at –70 °C until use. This method was
performed in accordance with a previous study [16] with
some modifications.
IBV live attenuated H120 serotype was obtained from
the Razi Vaccine and Serum Research Institute, in Iran,
and admixed with 3 doses of BLPs at 0.15, 0.3, and 0.6 mg
dry weight per bird. These BLP doses, except for the dose
administered to the BLP1 group (BLPs at 0.15 mg dry
weight per bird) were previously used by Wang et al. [11].
2.2. Experimental design
A total of 50 SPF chicken eggs were purchased from an
Indian company (Venky’s Poultry Products, Pune, MH,
India) and hatched in an incubator. Afterwards, these 50
SPF chickens were divided randomly into 5 equal groups.
While one group was not vaccinated (Unvaccinated group),
the other 4 groups (Control, BLP1, BLP2, and BLP3 groups)
were immunized at 1 day old with a single dose of Razi IBV
live attenuated H120 serotype via ocular administration,
and in addition, the BLP1, BLP2, and BLP3 groups received
the vaccine admixed with BLPs at 0.15, 0.3, and 0.6 mg dry
weight per bird, respectively.
2.3. Blood sample collection and ELISA assay
Blood was collected via brachial venipuncture from the
wings of 5 day-old SPF chickens on day 1 prevaccination
and then from 5 birds of each group (birds of each group
were marked with 5 different colored leg bands in advance)
weekly, for 35 days, in the same manner as mentioned above.
Blood samples on days 7, 14, 21, 28, and 35 postvaccination
(p.v.) were obtained and kept in microtubes at 4 °C in the
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refrigerator. A total of 130 samples were collected, and the
relevant sera were subsequently extracted by centrifugation
at 4000 × g for 5 min and stored at –20 °C until evaluation.
Sera samples were measured for titers of the IgG
antibodies against IB using the ELISA chicken IgG
antibodies kit, commercially available from IDVet (Grabels,
France), according to the manufacturer’s instructions.

± 4.93), and from days 1 to 7 p.v. in all of the groups (* <
102 ± 143.96), were consistently negligible. No significant
difference was observed among all groups within the first
7 days of the experiment (Table 1).
From days 7 to 14 p.v., a more prolonged serum IgG
response was observed in the BLP3 (from 102 ± 143.96
to 758 ± 1257.68) and Control (from 59 ± 16.64 to 866
± 530.10) groups when compared to the BLP1 (from 39.4
± 12.97 to 1897.60 ± 1266) and BLP2 (from 62.6 ± 51.97
to 1654.6 ± 1013.27) groups (Figure). On day 14 p.v., the
highest serum IgG titer levels were observed in the BLP1
group (1897.60 ± 1266); however, no significant differences
were detected between the serum IgG titers of the groups,
except in the BLP1 and the Unvaccinated groups (Table 1).
From days 14 to 21 p.v., the lowest among the vaccinated
groups surge was observed in the BLP2 group (from
1654.6 ± 1013.27 to 2641.8 ± 1682.71) (Figure). On day
21 p.v., the highest serum IgG titer levels were observed in
the BLP1 (3718.2 ± 640.96) group, whereas the serum IgG
values in the BLP2 and the BLP3 groups were within the
same range, while those of the Control group (2468.4 ±
433.12) were the lowest among the vaccinated groups. No
significant difference was observed between the serum IgG
titers of the vaccinated groups (Table 1).
From days 21 to 28 p.v., the highest surge in the serum
IgG titer levels was observed in the Control group (from
2468.4 ± 433.12 to 3614 ± 1161.82) when compared to the
other groups (Figure). On day 28 p.v., while the serum IgG
titer levels of the Control group (3614 ± 1161.82) exceed
those of the BLP2 group (3399.2 ± 2697.66), the serum IgG
values of the BLP2 and BLP3 groups were within the same
range. No significant difference was observed between the
serum titers of the vaccinated groups (Table 1).
From days 28 to 35 p.v., surprisingly, the serum
titer levels of the BLP3 group decreased (from 3405.4 ±

2.4. Recording of the weekly weight gain and feed
conversion ratio
All SPF chickens in the 5 groups were weighed weekly and
the measured weight values were recorded for later weight
gain evaluation. Weekly feed intake of the birds was also
recorded to estimate the feed conversion ratio (FCR) of
each group at the end of each week.
2.5. Postmortem examinations
From each group, 3 SPF chickens were euthanized at 35
days of age and different specific organs, such as the bursa
of fabricius, cecal tonsils, thymus, kidney, spleen, liver,
and lung, as well as trachea, were evaluated for probable
lesions.
2.6. Statistical analysis
Values of the anti-IBV serum IgG titers and weights
of the birds were presented as the mean ± SD. ANOVA
coupled with the Tukey post hoc test was used to compare
the means of the variables recorded among the groups.
Repeated measure ANOVA was used to analyze changes of
the variables of each group over time. Statistical analyses
were performed using SPSS software v.16 (SPSS Inc.,
Chicago, IL, USA). P < 0.05 was considered statistically
significant.
3. Results
3.1. IBV-specific IgG titers
Expectedly, over the duration of the experiment, the
serum IgG titer levels in the Unvaccinated group (* < 27.6

Table 1. Mean ± SD of the weekly recorded IBV-specific serum IgG titer levels in the 5 different groups of birds over the 35 days of the
experiment. Mean titer of the day-old chickens was 33.8 ± 16.28.

Groups

Sampling day
7

14

21

28

35

Unvaccinated

15.8 ± 3.83Aa

17 ± 3.08Aa

22.4 ± 2.4Aab

27.6 ± 4.93Ab

21.2 ± 3.03Aab

Control

59 ± 16.64Aa

866 ± 530.10ABa

BLP1

39.4 ± 12.97

BLP2
BLP3

2468.4 ± 433.12Bb

3614 ± 1161.82Bbc

4493.6 ± 934.5Bc

1897.60 ± 1266.19

3718.2 ± 640.96

4186.8 ± 1147.55

4964.8 ± 1566.1Bc

62.6 ± 51.97Aa

1654.6 ± 1013.27ABa

2641.8 ± 1682.71Ba

3399.2 ± 2697.66Ba

3724.4 ± 2892.68Ba

102 ± 143.96

758 ± 1257.68

2617 ± 1034.84

3405.4 ± 1469.81

3326 ± 1011.07Bc

Aa

Aa

Bab

ABab

Bbc

Bbc

Bc

Bc

Values with different superscripted uppercase letters indicate statistically significant differences among the groups at each time
point (P < 0.05).
a,b,c
Values with different superscripted lowercase letters indicate statistically significant differences between the data in the same row (P
< 0.05).
A, B, C
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Figure. Trend of the estimated means of the IBV-specific serum IgG titer levels using
ELISA among the 5 groups (Unvaccinated, Control, BLP1, BLP2, and BLP3) over the
35 days of the experiment.

1469.81 to 3326 ± 1011.07) (Figure). On day 35 p.v., the
serum IgG titer levels of the Control (4493.6 ± 934.5) and
BLP1 (4964.8 ± 1566.1) groups were higher than those of
the BLP2 (3724.4 ± 2892.68) and BLP3 (3326 ± 1011.07)
groups. No significant differences were observed between
the serum IgG titers of the vaccinated groups (Table 1).
On days 21, 28, and 35 p.v., a significant difference
was evident between the serum IgG titer levels of all the
vaccinated groups and the group receiving no vaccine
(Table 1).
3.2. Weights and FCR
The mean weights of the birds from the highest to the
lowest at each time point were in the BLP3, BLP2, BLP1,
Control, and Unvaccinated groups, respectively, except for
those in the Control group on day 21, which were higher
than those of the other groups, excluding the BLP3 group
(Table 2).
The lowest recorded FCR was in the BLP1 group
throughout the duration of the experiment, while those of
both the BLP3 and BLP2 groups were only lower during
week 1 (Table 3).
3.3. Necropsy lesions
While no pathologic alterations were observed in the
Unvaccinated, Control, BLP1, and BLP2 groups, 2 chickens
in the BLP3 group experienced bleeding in the trachea and
larynx, along with hemorrhages in the bursa of fabricius
and thymus. Minor pneumonia and nephritis, as well as
urate deposits in the kidneys, were other observations in
these 2 birds.

4. Discussion
This study evaluated BLPs as a novel adjuvant for IBV
vaccines in chickens and yielded promising results. As
the experiment was performed on SPF chickens, the
serum IgG titers were nonsignificant in the Unvaccinated
group over the duration of the study and in all of the
other groups over the first 7 days. It was assumed that
immune system immaturity at the time of vaccination was
responsible for such inadequate and/or delayed anti-IBV
immune response. Therefore, a significant rise in antibody
levels may take time to become evident [17]. This was
in accordance with a previous study where a significant
discrepancy was not observed until 28 days p.v. [18].
At the end of week 2, the titer levels in the BLP1
(1897.60 ± 1266.19) and BLP2 (1654.6 ± 1013.27) groups
were remarkable; however, they were nonsignificant when
compared to those of the Control (866 ± 530.10) and BLP3
(758 ± 1257.68) groups. Surprisingly, the titer levels of the
BLP3 group were the lowest among the vaccinated groups
(758 ± 1257.68) at the end of week 2. This could mean that
in comparison with a nonadjuvanted IBV vaccine, low
doses of BLPs (0.15 and 0.3 mg dry weight of BLPs per bird)
as a vaccine adjuvant were able to rapidly boost immune
response against IBV, particularly in younger birds.
The BLP3 group was the only vaccinated group to
exhibit a decrease in titer levels (from 3405.4 ± 1469.81
to 3326 ± 1011.07) in the final week p.v. The insufficient
serum IgGs response was observed in the BLP2 group to
a lesser extend as well, particularly when compared to the
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Table 2. Weekly mean weights of the 5 different groups of birds over the 35 days of the experiment (mean ± SD).

Groups

Sampling day
1

7

14

21

28

35

Unvaccinated

32 ± 2.3

47 ± 2.1

83.5 ± 4.7

133.5 ± 9.1

204 ± 16.9

278.5 ± 19Af

Control

33.2 ± 2.7Aa

50.5 ± 4.9Aa

91.5 ± 11.7ABb

174.5 ± 19.9Bc

225 ± 33.4ABd

307.2 ± 39.4ABe

BLP1

33.3 ± 1.6Aa

58.8 ± 4.7Bb

99.6 ± 17.3BCc

164.3 ± 24BCd

252.3 ± 31.3Be

341.3 ± 27.8BCf

BLP2

33.5 ± 2.2

60.3 ± 7

108.1 ± 16.8

173.3 ± 32.4

261.8 ± 45.6

345 ± 49.6BCe

BLP3

34.6 ± 3.3Aa

68.5 ± 5Cb

123 ± 9.9Dc

193.3 ± 18.5Cd

292.1 ± 29.2Ce

367 ± 41.3Cf

Aa

Ab

Aa

Ba

Ac

Ad

Cb

BCc

Ae

BCd

Values with different superscripted uppercase letters indicate statistically significant differences among the groups at each time
point (P < 0.05).
a,b,c,d,e,f
Values with different superscripted lowercase letters indicate statistically significant differences between the data in the same row
(P < 0.05).
A,B,C,D

Table 3. Weekly FCR records of the 5 different groups of birds during the
experiment.
Week 1

Week 2

Week 3

Week 4

Week 5

Unvaccinated

2.12

2.45

2.65

2.96

2.97

Control

1.73

2.21

1.77

2.52

2.85

BLP1

1.27

1.68

1.73

1.91

2.19

BLP2

1.24

2.01

2.36

2.63

2.84

BLP3

1.09

1.77

2.12

2.38

2.70

Control group, this results in further investigation in the
necropsy findings, such as hemorrhage in the lymphoid
organs including the bursa of fabricius and thymus of 2
individuals in the BLP3 group.
It was supposed that single-dose vaccine administration
could have been a reason for not observing a significant
discrepancy between the titers of the groups. As it was
expected to observe antibody alterations over a short period
such as 35 days, a booster vaccination was excluded, since it
could excessively complicate the results. As a consequence,
the low-dose BLP-adjuvanted IBV booster on days 7 or 14
p.v. may have resulted in significantly different possible
IgG titer levels in the BLP-treated groups. Due to a TLR
expression deficiency in chickens at early ages [17] and
considering that BLPs codelivered at 1 day old are a tolllike receptor 2 (TLR2) agonist [19], it was speculated that
the ultimate potential of the codelivered BLPs in inducing
expectative highly significant titer levels in this period
could not be attained. Nevertheless, further investigation is
required to support this hypothesis.
In addition to providing protective inflammation,
TLR agonists are also capable of amplifying exacerbated
inflammation, leading to pathological lesions [20]. It has
been shown that TLR2, TLR4, and TLR7 are involved in
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inflammation and renal problems, such as lupus nephritis
[21]. Moreover, it has been recognized that TLR7 signaling,
leading to interleukin-6 production, takes part in the
development of nephritis or tissue injuries in chickens
challenged with an IBV strain [22]. Therefore, it was opined
that an excess amount of BLPs, as was applied as a high dose
in the BLP3 group (0.6 mg dry weight of BLPs per bird),
may have caused unwanted inflammatory responses, since
renal lesions were observed in 2 chickens in this group.
The best weight records were observed in the BLP3
group (Table 2), even though the best FCR was recorded
in the BLP1 group (Table 3). As the mean weight records
showed, the codelivered BLPs were highly significantly
correlated with weight gain. Interpretation of the
performance results was difficult, and it seemed that there
existed a need for further investigation.
In summary, it was supposed that in developing a BLPadjuvanted IBV vaccine, the proper suggested dose of BLPs
for providing boosted humoral immune response could
be less than 0.3 mg dry weight of BLPs per bird, as was
administered in the BLP1 group (0.15 mg dry weight of
BLPs per bird) in the current study.
An argument exists regarding whether antibodies are
involved in preventing IB or not. In a study by Feng et al.

TOHIDI et al. / Turk J Vet Anim Sci
[7], it was revealed that local and cellular immunity, but
not humoral immunity, were involved in protection against
IBV. Moreover, it was shown by Bru et al. [15] that antiIBV antibodies were not always associated with protection.
Nevertheless, it was reported that locally-produced antiIBV IgGs induced by day old vaccination probably play a
role in protection against IBV, specifically in controlling
upper respiratory tract infection [18]. In another study
by Orr-Burks et al. [1], it was demonstrated that anti-IBV
IgA titers could be more correlated with protection when
compared to anti-IBV IgG titers; however, it was indicated
that tear antibody levels were not considered as an accurate
parameter of protection against IB. Furthermore, Lopes et
al. [23] stated that elicited mucosal IgG and IgA antibodies
in the respiratory tract, as well as cell-mediated immunity
responses, were important factors in preventing IBV
replication and protection against ciliostasis and lesions of
the trachea. It was assumed that IgGs are involved in the
protection of oviducts in layers by neutralizing IBV serum
antigens, resulting in prevention against the persistency of
IBV infection in chickens [24]. In a recent study, there existed
evidence that the ovaries were considerably less degenerated
in a group that received an inactivated booster after a
live vaccine than in a group receiving only a live vaccine
[24,25]. Feng et al. [7] stated that monitoring IgGs was of
crucial importance in evaluating the immune response to
an IBV challenge. In another study, the evaluation of serum
antibodies for predicting the potency of live IBV vaccination
was mentioned as improper since the antibody titer levels
induced by vaccination at an early age were low; however,
this method was preferred by some regulatory authorities
over performing in vivo protection studies [26]. Despite
all of the mentioned results, because the immune status of
poultry flocks is commonly assessed by serological assays,
the measurement of serum antibodies (IgGs) was therefore
considered in the design of this study.
It has been supposed that the presence of MDAs
impaired active immunization following day-old vaccination
nevertheless, some studies have shown that MDAs do
not may impair IBV vaccination, since local immunity is
probably of far more importance and serum antibodies are
not involved in this response [4]. In another experiment,
the transfer of B and T cell subpopulations to the upper
respiratory tract was not observed in SPF chickens. Thus,
despite minor neutralizing vaccine antigens, MDA appeared
to have no significant influence over responses induced by an
IBV vaccine unless it was administered on the day of hatching
[27]. In a study by van Ginkel et al. [17], it was purposed that
early immunization did not result in the expected innate and
adaptive immune responses. Chickens vaccinated on days
1, 7, or 14 after hatching displayed delayed serum antibody
response. Furthermore, a lower antibody production and IgG
avidity index, along with increased tracheal inflammation
and subsequently, lower protection, were all found in the

group vaccinated at 1 day old when compared to the other
groups. Thus, immunization at 1 week after hatching was
proposed as an alternative for the day-old vaccination. As the
lack of TLR expression in day-old chickens was probably the
cause of lower antibody affinity maturation and subsequently
lower protection, exploiting a TLR-activating adjuvant was
suggested to boost antibody production and elevate affinity
maturation in day-old chickens, which could consequently
help to avoid the challenges of vaccination at an early age
[17]. In this study, it was decided to administer day-old
vaccination for the birds since it is routinely performed in
poultry flocks in Iran as current practice.
BLPs are able to act as an adjuvant because they mediate
TLR2 signaling through their cell-wall components.
Neonatal DCs, CD4, and CD8+ cell stimulation, as well as
proinflammatory and Th1 polarizing cytokine secretion in
favor of biased Th1 type T cell response [28-31], along with
their role in Th17 activation in a TLR2-dependent manner
make their activity potent, even when simply mixed with a
subunit antigen. On the whole, TLR agonists, because of their
immune stimulation potency, have been noted as efficient
future adjuvants [32]. Thus, the TLR2 mediating activity of
BLPs, in addition to their safety properties, makes them an
eligible candidate as a promising alternative adjuvant for an
IBV vaccine.
Other successful applications of BLPs in previous studies
have included: the prevention of bacterial infections in early
life by L. lactis germ particles carrying vaccine antigens [33];
germ particles acting as a potent adjuvant for intranasal
influenza immunization [19]; BLP-adjuvanted influenza
vaccine, delivered via intranasal administration, enhancing
systemic and local antibody responses against influenza,
leading to protective resistance against homologous or
heterologous infection when compared to conventional
intramuscular immunization [31]; intranasal vaccination of
mice or cotton rats with BLPs resulting in potent induction of
recombinant fusion protein-specific immunoglobulins and
a significant decrease of virus titers in lungs with respiratory
syncytial virus challenge [34]; nasal immunization by BLP
mixed with split influenza vaccine inducing influenza A
virus-specific T cell and B cell responses, both systemically
and at the site of virus entry in a TLR2 dependent manner
[29]; Shigella invasion plasmid antigen B and D, displayed on
the BLPs of L. lactis, inducing protective immunity in adult
and infant mice [35]; pneumococcal surface protein, bound
with protein anchors of BLPs (BLPs/PspA-PA), efficiently
inducing IgG and IgA levels and providing complete
protection in mice challenged with pneumococci of different
PspA families [11]; intranasal pertussis vaccine with BLP
adjuvant enhanced immune responses and protected mice
from an intranasal challenge and pathological injury [30];
and recently, BLP based pneumococcal vaccine, displaying
PspA2 and PspA4 fragments, inducing broad protective
immune responses [36]. To the best of our knowledge, this
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experiment was the first attempt toward the application of
BLPs as a novel adjuvant for vaccines in the poultry industry.
Evidently, the results of the present study were in agreement
with those of previous studies, wherein BLPs are a robust
adjuvant for vaccines.
This study was a novel and primary attempt to understand
the efficiency of BLPs supplemented with a vaccine against
IB. Evaluation of mucosal and cellular immunity influenced
by the BLP-adjuvanted IBV vaccine was not considered in
this experiment despite its substantial duty in protection
[23]. Challenges were also not performed herein, although
they are essential to estimate the real potency of the applied
BLP-adjuvanted vaccine against a field strain [8,9,37]. Thus,
to further understand the immune system stimulating
potency of the BLP-adjuvanted vaccine, studies consisting
of challenges along with evaluating levels of immunity other
than humoral, in addition to viral load detection, as well as
ciliostasis and histopathology investigations are suggested.

In summary, it could be concluded that admixing low doses
of BLPs, such as 0.15 mg dry weight per bird, with a live
H120 IBV vaccine is capable of rapidly boosting higher antiIBV serum IgG titer levels than a nonadjuvanted live IBV
vaccine, even at 2 weeks after hatching.
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